Company News »

Investors of EDAP TMS S.A. With Losses of $50,000 or More Are Encouraged to Contact Law Offices of Howard G. Smith

Business Wire
Share on StockTwits
Published on

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of purchasers of the securities of EDAP TMS S.A. (“EDAP” or the “Company”) (NASDAQ:EDAP) between February 1, 2013 and July 30, 2014, inclusive (the “Class Period”). Investors who have losses of $50,000 or more are encouraged to contact the firm for more information.

EDAP, through its subsidiaries, develops, produces and markets minimally invasive medical devices for the treatment of urological diseases, including the Ablatherm-HIFU device for the treatment of organ-confined prostate cancer. The Complaint alleges that defendants misrepresented and/or failed to disclose that:

  • The Company overstated the efficacy and safety of its Ablatherm trials by relying on cross-study comparisons rather than a head-to-head trial.
  • The study’s survival endpoint was inappropriate for the patient population.
  • As a result of the above, the Company’s statements about its business and operations were materially false and misleading at all relevant times.

If you are a member of the Class described above, you have until October 3, 2014, to move the Court to serve as lead plaintiff, if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class.

If you suffered losses of $50,000 or more and wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to, or visit our website at

Share on StockTwits